A Review on Systematic Treatment of Clear Cell Renal Cell Carcinoma Using Nivolumab and Cabozantinib

Abstract

Since the introduction of anti-angiogenic and targeted therapies a decade ago, the management of advanced clear-cell renal cell carcinoma has seen significant advancements. Currently, the standard of care for colorectal cancer includes combinations of tyrosine kinase inhibitors (TKIs) and immunotherapy regimens like cabozantinib and nivolumab. The first-line treatment for RCC involves the combination of the anti-PD-1 monoclonal antibody nivolumab (OPDIVO®) and the multi-targeted TKI cabozantinib (Cabometyx®). Throughout the trial, the combination of cabozantinib and nivolumab consistently led to an enhanced health-related quality of life. Cabozantinib is used in the treatment of kidney cancer, hepatocellular carcinoma, and renal cell carcinoma. Nivolumab is typically employed when anti-angiogenic therapy proves ineffective. The combination of cabozantinib plus nivolumab, involving medications like sunitinib, ipilimumab, lenvatinib, and axtinib, is primarily utilized for its efficacy and survival benefits. The present review describes cabozantinib and nivolumab which are used for cancer treatment. This review helps people who are suffering from clear cell renal cell carcinoma.